NKTR

30.2007.19%
DM

Diana M. Brainard

Independent Director

Dr. Diana M. Brainard, MD.,serves as Entrepreneur-in-Residence at Atlas Venture Advisors, Inc. since 2026. She served as an Entrepreneur Partner at MPM Asset Management, L.L.C. since 2024. She served as an Executive Partner and Entrepreneur at MPM Asset Management, L.L.C. till December 2023. She serves as Director of Affinia Therapeutics Inc. since March 2022. She serves as an Independent Director at Nektar Therapeutics since November 2021. She is Chief Executive Officer and Director of ElevateBio company since May 17, 2021 and had been its Independent Non-Executive Director since July 2020 until May 17, 2021. She was Chief Executive Officer at AlloVir, Inc. since May 17, 2021 until December 19, 2024 and served as its Director from July 2020 to December 19, 2024. She has several years of experience in the biopharmaceutical industry and academic medicine, has authored several publications and advancing therapies for devastating diseases. Prior to joining MPM BioImpact, Dr. Brainard spent several years at Gilead, where she played an enterprise-wide leadership role as the head of the virology therapeutic area. Dr. Brainard had been Senior Vice President of HIV and Emerging Viral Infections at Gilead Sciences, Inc., since August 14, 2018. Dr. Brainard began her career in the biopharma industry at Merck & Co. where she held positions in clinical pharmacology and experimental medicine. Dr. Brainard served as Vice President of Clinical Research, Liver Diseases at Gilead Sciences, Inc. since 2015 until August 14, 2018. Dr. Brainard has served as Senior Vice President and Virology Therapeutic Area Head at Gilead Sciences, Inc. from 2018 to 2021. She oversaw the development and launch of the hepatitis C treatments Sovaldi, Harvoni and Epclusa and the HIV treatment Biktarvy. Dr. Brainard joined Gilead in 2010. She has extensive training and experience in immunology, infectious diseases and drug development. Under her leadership, Gilead received regulatory approval of four chronic hepatitis C virus (HCV) therapies in a period several years. In 2020, she led the company-wide initiative at Gilead to rapidly advance Veklury (remdesivir). Dr. Brainard obtained her BA degree in Literature from Brown University and her M.D. from Tulane University School of Medicine and completed her residency and fellowship in internal medicine and infectious diseases at Harvard University. After completing her residency at Massachusetts General Hospital, she served on the faculty of Harvard Medical School where she conducted NIH-funded research focused on HIV immunology and T-cell trafficking.

Positions